Suppr超能文献

托莱多省综合肾脏替代治疗项目的成本分析(2012 - 2013年)

Cost analysis of integrated renal replacement therapy program in the province of Toledo (2012-2013).

作者信息

Conde Olasagasti José L, Garcia Diaz José Eugenio, Carrasco Benitez Pilar, Mareque Ruiz Miguel Ángel, Parras Partido María Pilar, Moreno Alia Inmaculada, Jimenez Lopez Laura, Cia Lecumberri Juan José, Araque Pilar, Fernandez María Luisa

机构信息

Complejo Hospitalario de Toledo, Toledo, España.

Complejo Hospitalario de Toledo, Toledo, España.

出版信息

Nefrologia. 2017 May-Jun;37(3):285-292. doi: 10.1016/j.nefro.2016.11.016.

Abstract

BACKGROUND

Renal replacement therapy (RRT) is the object of constant analysis in the search for efficiency and sustainability.

OBJECTIVE

To calculate the direct cost of healthcare for the prevalent RRT population in the province of Toledo (2012/2013).

METHOD

a) Population: All prevalent patients at some point in RRT in 2012 (669) and in 2013 (682). b) Costs included (€): 1) dialysis procedure; 2) inpatient, outpatient and emergency care, dialysis and non-dialysis related; 3) drug consumption; 4) medical transport. c) Calculation and analysis: The aggregate localized or reconstructed cost of each item was calculated from the individual cost of each patient. Annual cost and cost per patient/year was calculated for the whole RRT and for its subprograms (€).

RESULTS

a) Aggregate costs: The total cost of RRT amounted to 15.84 and 15.77 million euros (2012/2013). Dialysis procedures account for 40.2% of the total while the sum of hospital care and drug consumption represents 41.5%. Healthcare for patients on hospital haemodialysis (HHD) and combined haemodialysis (CHD), peritoneal dialysis (PD) and transplant (Tx) accounts for 70.0, 5.0 and 25.0% of the total respectively. b) Patient/year cost: From the number of patients/year provided by each subprogramme, the following values were obtained in 2012/2013: All RRT 26,130/25,379; HHD 49,167/53,289; CHD 44,657/44,971; PD 45,538/51,869 and Tx 10,909/10,984.

CONCLUSIONS

Our results are consistent with others published, although our patient/year values are slightly higher, probably because they include elements such as outpatient pharmacy, hospital and medical transport cargo. The growing contribution of Tx to the survival of the whole RRT population contains the overall costs and reduces the patient/year cost, making RRT sustainable.

摘要

背景

肾脏替代治疗(RRT)一直是寻求效率和可持续性过程中不断分析的对象。

目的

计算托莱多省(2012/2013年)RRT现患人群的医疗直接成本。

方法

a)人群:2012年(669例)和2013年(682例)在某个时间点接受RRT的所有现患患者。b)纳入的成本(欧元):1)透析程序;2)住院、门诊和急诊护理,与透析及非透析相关的;3)药物消耗;4)医疗运输。c)计算与分析:从每位患者的个体成本计算每项的汇总本地化或重构成本。计算整个RRT及其子项目的年度成本和每位患者/每年的成本(欧元)。

结果

a)汇总成本:RRT的总成本在2012/2013年分别为1584万欧元和1577万欧元。透析程序占总成本的40.2%,而医院护理和药物消耗的总和占41.5%。医院血液透析(HHD)、联合血液透析(CHD)、腹膜透析(PD)和移植(Tx)患者的医疗保健分别占总数的70.0%、5.0%和25.0%。b)患者/每年成本:根据每个子项目提供的每年患者数量,在2012/2013年获得以下数值:所有RRT为26,130/25,379;HHD为49,167/53,289;CHD为44,657/44,971;PD为45,538/51,869;Tx为10,909/10,984。

结论

我们的结果与其他已发表的结果一致,尽管我们的患者/每年数值略高,可能是因为它们包括门诊药房、医院和医疗运输费用等项目。Tx对整个RRT人群生存率的贡献不断增加,控制了总体成本并降低了患者/每年成本,使RRT具有可持续性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验